Suneel K. Gupta Ph.D.
Net Worth

Last updated:

What is Suneel K. Gupta Ph.D. net worth?

The estimated net worth of Dr. Suneel K. Gupta Ph.D. is at least $24,846,795 as of 26 Nov 2024. He owns shares worth $15,004,445 as insider, has earned $5,760,430 from insider trading and has received compensation worth at least $4,081,920 in Protagonist Therapeutics, Inc..

What is the salary of Suneel K. Gupta Ph.D.?

Dr. Suneel K. Gupta Ph.D. salary is $680,320 per year as Chief Devel. Officer in Protagonist Therapeutics, Inc..

How old is Suneel K. Gupta Ph.D.?

Dr. Suneel K. Gupta Ph.D. is 67 years old, born in 1958.

What stocks does Suneel K. Gupta Ph.D. currently own?

As insider, Dr. Suneel K. Gupta Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Protagonist Therapeutics, Inc. (PTGX) Chief Devel. Officer 266,983 $56.2 $15,004,445

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

PTGX logo
PTGX
Protagonist Therapeutics, Inc.
$56.2

Suneel K. Gupta Ph.D. insider trading

Protagonist Therapeutics, Inc.

Dr. Suneel K. Gupta Ph.D. has made 3 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 175,000 units of PTGX stock on 25 Nov 2024. As of 26 Nov 2024 he still owns at least 266,983 units of PTGX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 30,000 $12.17 $365,100
Sale
Common Stock 19,191 $45.5 $873,191
Option
Common Stock 30,000 $12.17 $365,100
Option
Common Stock 450 $12.17 $5,477
Option
Stock Option (right to buy) 450 $12.17 $5,477
Option
Stock Option (right to buy) 175,000 $7.73 $1,353,275
Option
Common Stock 45,000 $7.38 $332,100
Option
Common Stock 45,000 $8.02 $360,900
Option
Common Stock 85,000 $7.8 $663,000
Sale
Common Stock 103,437 $46.04 $4,762,239
Option
Common Stock 5,000 $7.38 $36,900
Sale
Common Stock 5,000 $25 $125,000
Option
Stock Option (right to buy) 5,000 $7.38 $36,900
Option
Stock Option (right to buy) 20,000 $7.38 $147,600
Option
Common Stock 20,000 $7.38 $147,600
Option
Common Stock 40,000 $7.38 $295,200
Option
Stock Option (right to buy) 40,000 $7.38 $295,200
Purchase
Common Stock 30,000 N/A N/A
Option
Stock Option (right to buy) 110,000 N/A N/A

Protagonist Therapeutics key executives

Protagonist Therapeutics, Inc. executives and other stock owners filed with the SEC: